CAR-T Therapy Overcomes Poor Prognosis in High-Grade B-Cell Lymphoma

A recent study published in Blood Advancesreveals that CAR-T cell therapy offers significant clinical benefits for patients with high-grade B-Cell Lymphoma (HGBL), a particularly aggressive form of large B-cell lymphoma (LBCL). The DESCAR-T LYSA study, conducted by French researchers, focused on patients who received CAR-T therapy as a third-line treatment or beyond, including those with MYC and BCL2 and/or BCL6 rearrangements—known as “double-hit” or “triple-hit” lymphoma.

The study enrolled 228 patients from the French DESCAR-T registry, of which 73 were diagnosed with HGBL, while the remaining 155 had non-HGBL LBCL. The study aimed to evaluate the safety and effectiveness of CAR-T therapy in these groups, with an average follow-up time of 18.5 months.

The findings revealed that the overall response rates (ORR) and complete response (CR) rates were comparable between HGBL and non-HGBL patients, at 68% and 60% for HGBL, and 76% and 59% for non-HGBL, respectively (p=0.293 and p=0.923). Furthermore, the median progression-free survival (PFS) for HGBL patients was 3.2 months, compared to 4.5 months for non-HGBL patients, although this difference was not statistically significant (p=0.103). Similarly, the median overall survival (OS) was 15.4 months for HGBL patients versus 18.3 months for non-HGBL patients (p=0.214).

Interestingly, when the OS was calculated from the date patients became eligible for CAR-T therapy, the median OS for HGBL patients dropped to 7.6 months, compared to 11.8 months for non-HGBL patients (p=0.062), showing that the timing of CAR-T administration plays a critical role in improving outcomes.

Among different subtypes of HGBL, those with MYC-BCL2 double-hit lymphoma had the poorest outcomes, with a median OS of only 6.6 months, significantly lower than other HGBL subtypes (HGBL-DH MYC-BCL6: 13.6 months, HGBL-NOS: 18.5 months) and non-HGBL patients (11.8 months). Despite this, no significant difference in OS or PFS was found when comparing the time of CAR-T infusion.

The safety of CAR-T therapy was consistent across both HGBL and non-HGBL groups. The occurrence of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) was similar between the two groups. However, 38% of HGBL patients required ICU care for CRS, although this was comparable to the treatment requirements seen in non-HGBL patients.

The DESCAR-T LYSA study highlights CAR-T therapy’s potential in improving the prognosis of patients with HGBL, even in later lines of treatment. While CAR-T may not completely overcome the poor prognosis associated with certain high-risk subtypes, such as double-hit HGBL, the study encourages early intervention with CAR-T therapy, which may offer better survival outcomes. Moreover, minimizing the time between leukapheresis and CAR-T infusion could be crucial for patients with aggressive disease like HGBL.

This research underscores the importance of CAR-T therapy as an effective treatment for high-grade B-cell lymphoma and provides valuable insights into optimizing treatment timelines for better patient outcomes. Further studies are needed to explore ways to enhance the efficacy of CAR-T therapy, particularly in challenging lymphoma subtypes.